These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26551678)

  • 1. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.
    Albrecht I; Wick C; Hallgren Å; Tjärnlund A; Nagaraju K; Andrade F; Thompson K; Coley W; Phadke A; Diaz-Gallo LM; Bottai M; Nennesmo I; Chemin K; Herrath J; Johansson K; Wikberg A; Ytterberg AJ; Zubarev RA; Danielsson O; Krystufkova O; Vencovsky J; Landegren N; Wahren-Herlenius M; Padyukov L; Kämpe O; Lundberg IE
    J Clin Invest; 2015 Dec; 125(12):4612-24. PubMed ID: 26551678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory myopathies: Anti-FHL1 antibodies linked to IIM.
    Barranco C
    Nat Rev Rheumatol; 2016 Jan; 12(1):2. PubMed ID: 26607388
    [No Abstract]   [Full Text] [Related]  

  • 3. Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort.
    Galindo-Feria AS; Horuluoglu B; Day J; Fernandes-Cerqueira C; Wigren E; Gräslund S; Proudman S; Lundberg IE; Limaye V
    Rheumatology (Oxford); 2022 Oct; 61(10):4145-4154. PubMed ID: 35022656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FHL1 mutants that cause clinically distinct human myopathies form protein aggregates and impair myoblast differentiation.
    Wilding BR; McGrath MJ; Bonne G; Mitchell CA
    J Cell Sci; 2014 May; 127(Pt 10):2269-81. PubMed ID: 24634512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing body myopathy and other FHL1-related muscular disorders.
    Schessl J; Feldkirchner S; Kubny C; Schoser B
    Semin Pediatr Neurol; 2011 Dec; 18(4):257-63. PubMed ID: 22172421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.
    Sherman MA; Graf R; Sabbagh SE; Galindo-Feria AS; Pinal-Fernandez I; Pak K; Kishi T; Flegel WA; Targoff IN; Miller FW; Lundberg IE; Rider LG; Mammen AL;
    Rheumatology (Oxford); 2023 Feb; 62(SI2):SI226-SI234. PubMed ID: 35961028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1.
    Windpassinger C; Schoser B; Straub V; Hochmeister S; Noor A; Lohberger B; Farra N; Petek E; Schwarzbraun T; Ofner L; Löscher WN; Wagner K; Lochmüller H; Vincent JB; Quasthoff S
    Am J Hum Genet; 2008 Jan; 82(1):88-99. PubMed ID: 18179888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective muscle involvement in a family affected by a second LIM domain mutation of fhl1: an imaging study using computed tomography.
    Komagamine T; Kawai M; Kokubun N; Miyatake S; Ogata K; Hayashi YK; Nishino I; Hirata K
    J Neurol Sci; 2012 Jul; 318(1-2):163-7. PubMed ID: 22541254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A zebrafish model for FHL1-opathy reveals loss-of-function effects of human FHL1 mutations.
    Keßler M; Kieltsch A; Kayvanpour E; Katus HA; Schoser B; Schessl J; Just S; Rottbauer W
    Neuromuscul Disord; 2018 Jun; 28(6):521-531. PubMed ID: 29735270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle hypertrophy as the presenting sign in a patient with a complete FHL1 deletion.
    Willis TA; Wood CL; Hudson J; Polvikoski T; Barresi R; Lochmüller H; Bushby K; Straub V
    Clin Genet; 2016 Aug; 90(2):166-70. PubMed ID: 27409453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exome Sequencing Identified a Splice Site Mutation in FHL1 that Causes Uruguay Syndrome, an X-Linked Disorder With Skeletal Muscle Hypertrophy and Premature Cardiac Death.
    Xue Y; Schoser B; Rao AR; Quadrelli R; Vaglio A; Rupp V; Beichler C; Nelson SF; Schapacher-Tilp G; Windpassinger C; Wilcox WR
    Circ Cardiovasc Genet; 2016 Apr; 9(2):130-5. PubMed ID: 26933038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy.
    Selcen D; Bromberg MB; Chin SS; Engel AG
    Neurology; 2011 Nov; 77(22):1951-9. PubMed ID: 22094483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders.
    Malfatti E; Olivé M; Taratuto AL; Richard P; Brochier G; Bitoun M; Gueneau L; Laforêt P; Stojkovic T; Maisonobe T; Monges S; Lubieniecki F; Vasquez G; Streichenberger N; Lacène E; Saccoliti M; Prudhon B; Alexianu M; Figarella-Branger D; Schessl J; Bonnemann C; Eymard B; Fardeau M; Bonne G; Romero NB
    J Neuropathol Exp Neurol; 2013 Sep; 72(9):833-45. PubMed ID: 23965743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.
    Schessl J; Taratuto AL; Sewry C; Battini R; Chin SS; Maiti B; Dubrovsky AL; Erro MG; Espada G; Robertella M; Saccoliti M; Olmos P; Bridges LR; Standring P; Hu Y; Zou Y; Swoboda KJ; Scavina M; Goebel HH; Mitchell CA; Flanigan KM; Muntoni F; Bönnemann CG
    Brain; 2009 Feb; 132(Pt 2):452-64. PubMed ID: 19181672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel FHL1 mutation in a family with reducing body myopathy.
    Schreckenbach T; Henn W; Kress W; Roos A; Maschke M; Feiden W; Dillmann U; Schulz JB; Weis J; Claeys KG
    Muscle Nerve; 2013 Jan; 47(1):127-34. PubMed ID: 23169582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy.
    McElhanon KE; Young N; Hampton J; Paleo BJ; Kwiatkowski TA; Beck EX; Capati A; Jablonski K; Gurney T; Perez MAL; Aggarwal R; Oddis CV; Jarjour WN; Weisleder N
    J Clin Invest; 2020 Aug; 130(8):4440-4455. PubMed ID: 32687067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic heterogeneity in British patients with a founder mutation in the FHL1 gene.
    Sarkozy A; Windpassinger C; Hudson J; Dougan CF; Lecky B; Hilton-Jones D; Eagle M; Charlton R; Barresi R; Lochmüller H; Bushby K; Straub V
    Eur J Hum Genet; 2011 Oct; 19(10):1038-44. PubMed ID: 21629301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy.
    Cowling BS; McGrath MJ; Nguyen MA; Cottle DL; Kee AJ; Brown S; Schessl J; Zou Y; Joya J; Bönnemann CG; Hardeman EC; Mitchell CA
    J Cell Biol; 2008 Dec; 183(6):1033-48. PubMed ID: 19075112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FHL1-related myopathy may not be classified by reducing bodies in muscle biopsy.
    Chen T; Lu X; Shi Q; Guo J; Wang H; Wang Q; Yin X; Zhang Y; Pu C; Zhou D
    Neuromuscul Disord; 2020 Feb; 30(2):165-172. PubMed ID: 32001145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies.
    Arouche-Delaperche L; Allenbach Y; Amelin D; Preusse C; Mouly V; Mauhin W; Tchoupou GD; Drouot L; Boyer O; Stenzel W; Butler-Browne G; Benveniste O
    Ann Neurol; 2017 Apr; 81(4):538-548. PubMed ID: 28224701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.